0001193125-24-033095.txt : 20240213 0001193125-24-033095.hdr.sgml : 20240213 20240213101356 ACCESSION NUMBER: 0001193125-24-033095 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 GROUP MEMBERS: BIOTECH TARGET N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Wave Life Sciences Ltd. CENTRAL INDEX KEY: 0001631574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: U0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-89180 FILM NUMBER: 24623165 BUSINESS ADDRESS: STREET 1: 7 STRAITS VIEW STREET 2: #12-00, MARINA ONE EAST TOWER CITY: SINGAPORE STATE: U0 ZIP: 018936 BUSINESS PHONE: 617-949-2900 MAIL ADDRESS: STREET 1: 733 CONCORD AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: WAVE Life Sciences Ltd. DATE OF NAME CHANGE: 20170516 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences Ltd. DATE OF NAME CHANGE: 20151106 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences LTD. DATE OF NAME CHANGE: 20151106 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 SC 13G/A 1 d740975dsc13ga.htm SC 13G/A SC 13G/A

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

 

 

WAVE LIFE SCIENCES LTD.

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

Y95308105

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. Y95308105

 

 1.   

 Names of Reporting Persons

 

 BB Biotech AG

 2.  

 Check the Appropriate Box if a Member of a Group (See Instructions)

 

 (a) ☒  (b) ☐

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

 Switzerland

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

with:

    5.   

 Sole Voting Power

 

 0

   6.  

 Shared Voting Power

 

 4,494,458

   7.  

 Sole Dispositive Power

 

 0

   8.  

 Shared Dispositive Power

 

 4,494,458

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 4,494,458

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented by amount in Row (9)

 

 3.7%

12.  

 Type of Reporting Person (See Instructions)

 

 HC, CO

 

2 of 6

CUSIP No. Y95308105

 

 1.   

 Names of Reporting Persons

 

 Biotech Target N.V.

 2.  

 Check the Appropriate Box if a Member of a Group (See Instructions)

 

 (a) ☒  (b) ☐

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

 Curaçao

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

with:

    5.   

 Sole Voting Power

 

 0

   6.  

 Shared Voting Power

 

 4,494,458

   7.  

 Sole Dispositive Power

 

 0

   8.  

 Shared Dispositive Power

 

 4,494,458

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 4,494,458

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented by amount in Row (9)

 

 3.7%

12.  

 Type of Reporting Person (See Instructions)

 

 CO

 

3 of 6

Item 1

1(a) Name of Issuer: Wave Life Sciences Ltd.

1(b) Address of Issuer’s Principal Executive Offices:

7 Straits View #12-00, Marina One East Tower, Singapore 018936

Item 2

2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Target N.V. (“Biotech Target”)

2(b) Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c) Citizenship: BB Biotech AG: Switzerland

     Biotech Target N.V.: Curaçao

2(d) Title of Class of Securities: Ordinary shares, no par value

2(e) CUSIP Number: Y95308105

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned: 4,494,458

 

  (b)

Percent of class: 3.7%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote 0

 

  (ii)

Shared power to vote or to direct the vote 4,494,458

 

  (iii)

Sole power to dispose or to direct the disposition of 0

 

  (iv)

Shared power to dispose or to direct the disposition of 4,494,458

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

 

4 of 6

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

BB Biotech AG      
Date: February 6, 2024    By:   

/s/ Martin Gubler

         Signatory Authority
      Name:    Martin Gubler
      Title:    Signatory Authority
Date: February 6, 2024    By:   

/s/ Ivo Betschart

         Signatory Authority
      Name:    Ivo Betschart
      Title:    Signatory Authority
Biotech Target N.V.      
Date: February 6, 2024    By:   

/s/ Jan Bootsma

         Signatory Authority
      Name:    Jan Bootsma
      Title:    Signatory Authority
Date: February 6, 2024    By:   

/s/ Hugo van Neutegem

         Signatory Authority
      Name:    Hugo van Neutegem
      Title:    Signatory Authority

 

5 of 6

Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*

 

*

Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.’s Schedule 13G filed with the Securities and Exchange Commission on December 23, 2019.

 

6 of 6